Associations between genetic polymorphisms of membrane transporter genes and prognosis after chemotherapy: meta-analysis and finding from Seoul Breast Cancer Study (SEBCS)

[1]  Joo-Youn Cho,et al.  Targeted Next‐Generation Sequencing for Comprehensive Genetic Profiling of Pharmacogenes , 2017, Clinical pharmacology and therapeutics.

[2]  M. Szczyrek,et al.  Polymorphisms of Genes Encoding Multidrug Resistance Proteins as a Predictive Factor for Second-Line Docetaxel Therapy in Advanced Non-small Cell Lung Cancer , 2016, Pathology & Oncology Research.

[3]  J. Ji,et al.  ABCC2-24C > T polymorphism is associated with the response to platinum/5-Fu-based neoadjuvant chemotherapy and better clinical outcomes in advanced gastric cancer patients , 2016, Oncotarget.

[4]  M. Morita,et al.  Translocation of the ABC transporter ABCD4 from the endoplasmic reticulum to lysosomes requires the escort protein LMBD1 , 2016, Scientific Reports.

[5]  N. Habermann,et al.  SNPs in transporter and metabolizing genes as predictive markers for oxaliplatin treatment in colorectal cancer patients , 2016, International journal of cancer.

[6]  Bingshu E. Chen,et al.  ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients. , 2016, Cancer epidemiology.

[7]  Kyu-Won Jung,et al.  Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2013 , 2016, Cancer research and treatment : official journal of Korean Cancer Association.

[8]  C. Ricciardelli,et al.  The role of ABC transporters in ovarian cancer progression and chemoresistance. , 2015, Critical reviews in oncology/hematology.

[9]  Ademar Lopes,et al.  Down-Regulation of SLC8A1 as a Putative Apoptosis Evasion Mechanism by Modulation of Calcium Levels in Penile Carcinoma. , 2015, The Journal of urology.

[10]  K. Giacomini,et al.  SLC transporters as therapeutic targets: emerging opportunities , 2015, Nature Reviews Drug Discovery.

[11]  Xueqin Chen,et al.  Impact of ABCG2 polymorphisms on the clinical outcome of TKIs therapy in Chinese advanced non-small-cell lung cancer patients , 2015, Cancer Cell International.

[12]  W. Han,et al.  Prediction of Breast Cancer Survival Using Clinical and Genetic Markers by Tumor Subtypes , 2015, PloS one.

[13]  Hyunsoon Cho,et al.  Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015 , 2018, Cancer research and treatment : official journal of Korean Cancer Association.

[14]  W. Han,et al.  ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy , 2014, Cancer science.

[15]  Huiyu Wang,et al.  Effect of hENT1 polymorphism G-706C on clinical outcomes of gemcitabine-containing chemotherapy for Chinese non-small-cell lung cancer patients. , 2014, Cancer epidemiology.

[16]  C. Ulrich,et al.  Polymorphisms in folate‐metabolizing enzymes and response to 5‐fluorouracil among patients with stage II or III rectal cancer (INT‐0144; SWOG 9304) , 2014, Cancer.

[17]  P. Baade,et al.  Incidence and mortality of female breast cancer in the Asia-Pacific region , 2014, Cancer biology & medicine.

[18]  Piotr Zawierucha,et al.  Drug transporter expression profiling in chemoresistant variants of the A2780 ovarian cancer cell line. , 2014, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[19]  J. Sanderson,et al.  Pharmacogenetics of pemetrexed combination therapy in lung cancer: pathway analysis reveals novel toxicity associations , 2014, The Pharmacogenomics Journal.

[20]  J. S. Lee,et al.  Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2011 , 2014, Cancer research and treatment : official journal of Korean Cancer Association.

[21]  J. Ahn,et al.  Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy. , 2014, European journal of cancer.

[22]  Juan Cai,et al.  SLCO1B1 and SLC19A1 Gene Variants and Irinotecan-Induced Rapid Response and Survival: A Prospective Multicenter Pharmacogenetics Study of Metastatic Colorectal Cancer , 2013, PloS one.

[23]  Dan M Roden,et al.  Genome-wide association studies in pharmacogenomics: successes and lessons , 2013, Pharmacogenetics and genomics.

[24]  W. Han,et al.  Association between chronological change of reproductive factors and breast cancer risk defined by hormone receptor status: results from the Seoul Breast Cancer Study , 2013, Breast Cancer Research and Treatment.

[25]  M. Wei,et al.  Association of ABCB1 genetic polymorphisms with susceptibility to colorectal cancer and therapeutic prognosis. , 2013, Pharmacogenomics.

[26]  E. Delpire,et al.  Physiology of SLC12 transporters: lessons from inherited human genetic mutations and genetically engineered mouse knockouts. , 2013, American journal of physiology. Cell physiology.

[27]  P. Souček,et al.  The expression profile of ATP-binding cassette transporter genes in breast carcinoma. , 2013, Pharmacogenomics.

[28]  Young Hak Kim,et al.  Population Pharmacokinetics/Pharmacodynamics of Erlotinib and Pharmacogenomic Analysis of Plasma and Cerebrospinal Fluid Drug Concentrations in Japanese Patients with Non-Small Cell Lung Cancer , 2013, Clinical Pharmacokinetics.

[29]  Kyong-Ah Yoon,et al.  Prognostic implications of genetic variants in advanced non-small cell lung cancer: a genome-wide association study. , 2013, Carcinogenesis.

[30]  Michael Thomas,et al.  A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis , 2012, International journal of cancer.

[31]  A. Kargi,et al.  MDR1 single nucleotide polymorphism C3435T in Turkish patients with non-small-cell lung cancer. , 2012, Gene.

[32]  E. Shoubridge,et al.  Mutations in ABCD4 cause a new inborn error of vitamin B12 metabolism , 2012, Nature Genetics.

[33]  Joon-Oh Park,et al.  Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine. , 2012, Pharmacogenomics.

[34]  Liancong Wang,et al.  Lack of association between MDR1 C3435T polymorphism and chemotherapy response in advanced breast cancer patients: evidence from current studies , 2012, Molecular Biology Reports.

[35]  T. Čufer,et al.  Predictive value of ABCB1 polymorphisms G2677T/A, C3435T, and their haplotype in small cell lung cancer patients treated with chemotherapy , 2012, Journal of Cancer Research and Clinical Oncology.

[36]  Y. J. Kim,et al.  A genome-wide association study identifies a breast cancer risk variant in ERBB4 at 2q34: results from the Seoul Breast Cancer Study , 2012, Breast Cancer Research.

[37]  Jian-hua Zhao,et al.  Polymorphisms in genes involved in drug detoxification and clinical outcomes of anthracycline-based neoadjuvant chemotherapy in Chinese Han breast cancer patients , 2012, Cancer biology & therapy.

[38]  Hua Zhao,et al.  Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study. , 2012, Gynecologic oncology.

[39]  Krishna R. Kalari,et al.  Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer , 2012, Pharmacogenetics and genomics.

[40]  F. Madeo,et al.  Polyamines in aging and disease , 2011, Aging.

[41]  S. Chanock,et al.  Genetic Effects and Modifiers of Radiotherapy and Chemotherapy on Survival in Pancreatic Cancer , 2011, Pancreas.

[42]  Eunjung Lee,et al.  Prediction of cancer prognosis with the genetic basis of transcriptional variations. , 2011, Genomics.

[43]  P. Bogner,et al.  3-D Conformal Photon Boost in the Treatment of Early Stage Breast Cancer: Four Year Follow Up Results , 2011, Pathology & Oncology Research.

[44]  W. Vach,et al.  Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer , 2011, European Journal of Clinical Pharmacology.

[45]  Donghui Li,et al.  Association of multi‐drug resistance gene polymorphisms with pancreatic cancer outcome , 2011, Cancer.

[46]  M. Shin,et al.  BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin , 2010, Cancer science.

[47]  A. Daly,et al.  Genome-wide association studies in pharmacogenomics , 2010, Nature Reviews Genetics.

[48]  D. Schaid,et al.  Glutathione Pathway Genetic Polymorphisms and Lung Cancer Survival After Platinum-Based Chemotherapy , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[49]  D Jamieson,et al.  Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide , 2010, British Journal of Cancer.

[50]  H. Chung,et al.  Association of the ABCB1 3435C>T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy. , 2009, Oncology reports.

[51]  P. Rosenberg,et al.  Pathway analysis by adaptive combination of P‐values , 2009, Genetic epidemiology.

[52]  J. Noël,et al.  Molecular characterization of a human cation‐Cl− cotransporter (SLC12A8A, CCC9A) that promotes polyamine and amino acid transport , 2009, Journal of cellular physiology.

[53]  J. Crowley,et al.  Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  H. Bartsch,et al.  Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients , 2009, International journal of cancer.

[55]  Vasilis Vasiliou,et al.  Human ATP-binding cassette (ABC) transporter family , 2009, Human Genomics.

[56]  D. Nebert,et al.  Analysis and update of the human solute carrier (SLC) gene superfamily , 2009, Human Genomics.

[57]  R. Weinshilboum,et al.  Pharmacogenomics: candidate gene identification, functional validation and mechanisms. , 2008, Human molecular genetics.

[58]  K. Byth,et al.  ABCB1 (MDR 1) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy , 2008, Clinical Cancer Research.

[59]  A. J. Kogan,et al.  Translating cancer trial endpoints into the language of managed care. , 2008, Biotechnology healthcare.

[60]  J. Lytton.  Na+/Ca2+ exchangers: three mammalian gene families control Ca2+ transport. , 2007, The Biochemical journal.

[61]  D. Berry,et al.  Effect of screening and adjuvant therapy on mortality from breast cancer , 2005 .

[62]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[63]  J. Gligorov,et al.  Preclinical pharmacology of the taxanes: implications of the differences. , 2004, The oncologist.

[64]  N. Davidson,et al.  Pharmacogenetics in the treatment of breast cancer , 2004, The Pharmacogenomics Journal.

[65]  Jonathan C. Cohen,et al.  Selective sterol accumulation in ABCG5/ABCG8-deficient mice Published, JLR Papers in Press, December 1, 2003. DOI 10.1194/jlr.M300377-JLR200 , 2004, Journal of Lipid Research.

[66]  T. Janvilisri,et al.  Sterol Transport by the Human Breast Cancer Resistance Protein (ABCG2) Expressed in Lactococcus lactis* , 2003, Journal of Biological Chemistry.

[67]  M. Erion,et al.  Isolation of a family of organic anion transporters from human liver and kidney. , 2001, Biochemical and biophysical research communications.

[68]  P. Donnelly,et al.  A new statistical method for haplotype reconstruction from population data. , 2001, American journal of human genetics.

[69]  H. McLeod,et al.  MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. , 2001, Pharmacogenetics.

[70]  N. Davidson,et al.  Combination of standard cytotoxic agents with polyamine analogues in the treatment of breast cancer cell lines. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[71]  Choi Sw.  Vitamin B12 deficiency: a new risk factor for breast cancer? , 1999 .

[72]  H. Seers,et al.  OUTCOME , 1977, How to Win Your Case.

[73]  B. Han,et al.  Influence of single nucleotide polymorphisms in ABCB 1 , ABCG 2 and ABCC 2 on clinical outcomes to paclitaxel-platinum chemotherapy in patients with non-small-cell lung cancer , 2016 .

[74]  Hong Zhao,et al.  Associations of ABCB1 and XPC genetic polymorphisms with susceptibility to colorectal cancer and therapeutic prognosis in a Chinese population. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[75]  David N. Rider,et al.  Polymorphisms in ABCB1 and ERCC2 associated with ovarian cancer outcome. , 2011, International journal of molecular epidemiology and genetics.

[76]  Y. Li,et al.  MDR1 gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. , 2011, Asian Pacific journal of cancer prevention : APJCP.

[77]  K. Matsuo,et al.  Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy. , 2010, Asian Pacific journal of cancer prevention : APJCP.

[78]  Richie Soong,et al.  Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients. , 2009, Lung cancer.

[79]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[80]  S. W. Choi.  Vitamin B12 deficiency: a new risk factor for breast cancer? , 1999, Nutrition reviews.